Firms fined £35m for colluding in drug supply to NHS
The NHS saw the price of an anti-sickness drug surge by 700% from £6.49 per pack of 50 tablets to £51.68 between 2013 and 2017, according to the CMA.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Five firms have been fined more than £35 million by the competition watchdog for colluding to restrict the supply of an anti-nausea tablet, sending costs to the NHS soaring by 700%.
The Competition and Markets Authority (CMA) said drugs firms Alliance Pharmaceuticals, Lexon, Medreich and former and current owners of Focus Advanz and private equity group Cinven broke the law by striking an illegal arrangement over the supply of Prochlorperazine – an important treatment for nausea, dizziness and migraines.
The NHS saw the price of the drug surge by 700% from £6.49 per pack of 50 tablets to £51.68 between 2013 and 2017, according to the CMA
This saw annual costs to the NHS for the drug soar from around £2.7 million to about £7.5 million, even though the number of packs dispensed fell.
The CMA’s investigation found the firms colluded to ensure a competitor was paid not to launch a product, which enabled price increases.
The CMA said Alliance appointed Focus as its distributor and Lexon and Medreich were paid a share of the profits earned by Focus on the supply of the Alliance drug.
In its findings, the regulator said that, before entering into the arrangement, Lexon and Medreich had been taking steps to launch their jointly developed rival drug.
Although Medreich obtained a licence to supply Prochlorperazine in January 2014, it did not supply the product until late 2017.
The CMA’s fines include £7.9 million for Alliance Pharmaceuticals, a £7.3 million fine for Lexon, a £4.6 million penalty for Medreich and a fine for Focus of £15.5 million, split between current owner Advanz and previous parent Cinven.
Medreich’s fine was reduced by 40% for admission and co-operation with the probe.
The CMA said Advanz, Cinven and Lexon have all been issued with fines in previous CMA pharmaceutical investigations, with penalties for Advanz and Cinven marking the first time a company has been fined by the watchdog in three separate investigations.
All firms should know that we will not hesitate to take action like this against any businesses that collude at the expense of the NHS
Chief executive Andrea Coscelli said: “These firms conspired to stifle competition in the supply of this important medication, so that the NHS – the main buyer of the drugs – lost the opportunity for increased choice and lower prices.
“While the arrangement was in place, the price increased significantly for a drug that people rely on to manage debilitating nausea, dizziness and migraines.”
He added: “All firms should know that we will not hesitate to take action like this against any businesses that collude at the expense of the NHS.”